Nemolizumab
From WikiMD's WELLNESSPEDIA
| Nemolizumab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | Subcutaneous injection |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | Proteolytic enzymes |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 1476039-58-3 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | D11080 |
Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis.[1] It is a monoclonal antibody that blocks the interleukin-31 receptor A.[2] Results of a Phase II clinical trial were published in March 2017.[3]
Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[4]
References[edit]
- ↑ H. Spreitzer."Neue Wirkstoffe - Nemolizumab".Österreichische Apothekerzeitung.27 March 2017;(7/2017)
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74".WHO Drug Information.2015;29(3)
- 411.Full text.
- ↑ "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis".New England Journal of Medicine.2017;376(9)
- 826–835.doi:10.1056/NEJMoa1606490.PMID:28249150.
- ↑ , Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma Full text, , Pharmabiz.com, 22 July 2016,
